U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
LA JOLLA, Calif., May 08, 2017 -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report first quarter 2017 financial results after the close of U.S. financial markets on May 15, 2017. Kura Oncology’s management will host a webcast and conference call at 4:30 p.m. EDT/1:30 p.m. PDT that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 877-516-3514 for domestic callers and 281-973-6129 for international callers and entering the conference code: 14001186. A live webcast and archive of the call will be available online from the investor relations section of the company website at www.kuraoncology.com. A telephone replay of the call will be available by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference code: 14001186.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. Kura’s pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 trial, and KO-539, an inhibitor of the menin-MLL protein-protein interaction, currently in preclinical testing. For additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.
CONTACT INFORMATION INVESTOR CONTACT: Robert H. Uhl Managing Director Westwicke Partners, LLC (858) 356-5932 [email protected] CORPORATE COMMUNICATIONS CONTACT: Mark Corbae Vice President Canale Communications (619) 849 5375 [email protected]
